D
David E. Newby
Researcher at University of Edinburgh
Publications - 902
Citations - 45577
David E. Newby is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Myocardial infarction & Coronary artery disease. The author has an hindex of 98, co-authored 805 publications receiving 35865 citations. Previous affiliations of David E. Newby include NHS Lothian & Queen's University.
Papers
More filters
Journal ArticleDOI
Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study
Gareth J. Padfield,Jehangir N. Din,Elena Koushiappi,Nicholas L. Mills,Simon D. Robinson,Nicholas L. Cruden,Andrew J. Lucking,Stanley Chia,Scott A Harding,David E. Newby +9 more
TL;DR: It is concluded that TNF-α antagonism is unlikely to be a beneficial therapeutic strategy in patients with acute myocardial infarction and etanercept reduces systemic inflammation but increases platelet activation without affecting peripheral vasomotor or fibrinolytic function.
Journal ArticleDOI
Altered Nitric Oxide Bioavailability Contributes to Diesel Exhaust Inhalation‐Induced Cardiovascular Dysfunction in Man
Jeremy P. Langrish,Jon Unosson,Jenny A. Bosson,Stefan Barath,Ala Muala,Scott Blackwell,Stefan Söderberg,Jamshid Pourazar,Ian L. Megson,AT Treweeke,Thomas Sandström,David E. Newby,Anders Blomberg,Nicholas L. Mills +13 more
TL;DR: Diesel exhaust inhalation disturbs normal vascular homeostasis with enhanced NO generation unable to compensate for excess consumption, and is suggested to be mediated through reduced NO bioavailability.
Journal ArticleDOI
PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Simon Wilson,Fraz A. Ismat,Zhaoqing Wang,Michael Cerra,Hafid Narayan,Jennifer Raftis,Timothy J. Gray,Shea P. Connell,Samira Garonzik,Xuewen Ma,Jing Yang,David E. Newby +11 more
TL;DR: The results suggest PAR4 antagonism has major potential as a therapeutic antiplatelet strategy and BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich thrombus formation under conditions of high shear stress.
Journal ArticleDOI
Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome.
Kuan Ken Lee,Amy V. Ferry,Atul Anand,Fiona E. Strachan,Andrew R. Chapman,Dorien M Kimenai,Steven J.R. Meex,Colin Berry,Iain N Findlay,Alan Reid,Anne Cruickshank,Alasdair Gray,Paul O. Collinson,Fred S. Apple,David A. McAllister,Donogh Maguire,Keith A.A. Fox,David E. Newby,Chris Tuck,Catriona Keerie,Christopher J. Weir,Anoop S V Shah,Nicholas L. Mills,High-STEACS Investigators +23 more
TL;DR: Use of sex-specific thresholds identified 5 times more additional women than men with myocardial injury, despite this increase, women received approximately one-half the number of treatments for coronary artery disease as men, and outcomes were not improved.
Journal ArticleDOI
High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome
Eve Miller-Hodges,Atul Anand,Anoop S V Shah,Andrew R. Chapman,Peter J. Gallacher,Kuan Ken Lee,Tariq E. Farrah,Nynke Halbesma,James P. Blackmur,David E. Newby,Nicholas L. Mills,Neeraj Dhaun +11 more
TL;DR: In suspected acute coronary syndrome, high-sensitivity cardiac troponin identified fewer patients with renal impairment as low risk and more as high risk, but with lower specificity for type 1 myocardial infarction.